Corporate Feature     

Published: May 31, 2024
Updated: May 31, 2024

Remedium Lifecare Ltd

Board approves 3:1 bonus issue: Robust earnings for FY24

Remedium Lifecare Ltd. (BSE: 539561), engaged in trading API intermediates (KSMs and CRMs) and various other raw materials essential to API trading, has come out with robust performance for the quarter and year ended 31 March 2024. Enthused by this performance, the board of directors has recommended a bonus issue of 3 equity shares for every 1 equity share held as on the record date decided for this purpose of course this is subject to approval from members and appropriate authorities. The record date for the bonus issue is 06 July 2024 (if approved by shareholders in AGM).

Remedium Lifecare Ltd., a company engaged in trading API intermediates (KSMs and CRMs) and various other raw materials essential to API trading, has bolstered its performance and presence within the pharmaceutical and healthcare domains by trading amino isophthalic acid, tellurium oxide, grignard reagent, iodine, selenium metal powder, trimethyl sulfoxonium iodide (TMSI). As a leading contract trader and brand owner of advanced intermediates and APIs, the company has shifted its paradigm into the trading of intermediates and APIs.

Reflecting the ethos of its Chairman, who believes in “working hard in silence and letting success make the noise,” Remedium is dedicated to upholding uncompromising quality standards. The company has consistently raised the industry’s benchmarks through its commitment to develop ing intermediates (KSMs & CRMs) and APIs that deliver unique value to patients and societies worldwide. Adapting swiftly to evolving demands, the company has emerged as one of the fastest-growing organizations in the global pharmaceutical industry.

“Quality is an ongoing process of building and sustaining relationships,” is the firm belief at Remedium. Its unwavering commitment to quality products is backed by a highly qualified team of professionals, a cutting-edge infrastructure, and deep industry knowledge. Remedium strives to create mutually beneficial partnerships, adhering to highquality standards as a matter of habit rather than chance.

Remedium is passionate about excellence and strives to deliver products with 0% defects, earning trust as a reliable source for quality pharmaceutical and healthcare products. It is committed to a rigorous product development process that involves constant modernization and adherence to international standards, since it has one of the largest portfolios of intermediates and active pharmaceutical ingredients (APIs), responsible for the therapeutic effects of various medicines.

Besides contributing to society’s wellbeing and health, the company’s vision is to become a well-known pharmaceutical multinational corporation in the pharmaceutical and healthcare industries. Remedium remains steadfast in its commitment to excellence, innovation, and societal well-being, driving positive change in the healthcare landscape.